Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in progressive interstitial lung disease with inflammatory component
NCT05596786Phase 3Recruiting
- Sponsor
- University Hospital Tours
- Start
- Jan 2023
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in interstitial lung disease (ILD), sponsored by University Hospital Tours. Started Jan 2023; status: recruiting.
02
Drugs
rituximab
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT05596786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05596786.